Patents by Inventor Ryan M. O'Connell

Ryan M. O'Connell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10435689
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: October 8, 2019
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Publication number: 20180187193
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 5, 2018
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 9862948
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cebp?, and Bach1, and the like.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: January 9, 2018
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Publication number: 20160244754
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: February 4, 2016
    Publication date: August 25, 2016
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 9290761
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csflr, HIF1?, Sla, Cepb?, and Bach1, and the like.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: March 22, 2016
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 9006195
    Abstract: The present disclosure relates to regulation of functions of hematopoietic stem cells (HSCs) by delivering of miRNAs, including miR-125b, miR-126, and miR-155, to HSCs. For example, in some embodiments, blood output in a mammal can be increased by administering miR-125b, miR-126, and/or miR-155 oligonucleotides. Also disclosed are methods for promoting hematopoietic stem cell engraftment and method for treating a myeloproliferative disorder.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: April 14, 2015
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Ryan M. O'Connell
  • Publication number: 20140220049
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csflr, HIFl?, Sla, Cepb?, and Bach1, and the like.
    Type: Application
    Filed: December 23, 2013
    Publication date: August 7, 2014
    Applicant: California Institute of Technology
    Inventors: David Baltimore, Ryan M. O'Connell, Konstantin Taganov, Mark Boldin
  • Patent number: 8685727
    Abstract: The present disclosure relates to regulation of macrophage activation by delivering of miRNAs, for example miR-125b or anti-miR-125b, to macrophages. For example, in some embodiments, macrophage activation can be elevated or reduced by administering miR-125b or anti-miR-125b oligonucleotides. Also disclosed are methods for promoting T cell activation and method for treating various disorders such as tumor and autoimmune diseases.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: April 1, 2014
    Assignee: California Institute of Technology
    Inventors: Aadel Chaudhuri, Alex Steven So, David Baltimore, Ryan M. O'Connell
  • Publication number: 20120322854
    Abstract: The present disclosure relates to regulation of macrophage activation by delivering of miRNAs, for example miR-125b or anti-miR-125b, to macrophages. For example, in some embodiments, macrophage activation can be elevated or reduced by administering miR-125b or anti-miR-125b oligonucleotides. Also disclosed are methods for promoting T cell activation and method for treating various disorders such as tumor and autoimmune diseases.
    Type: Application
    Filed: June 18, 2012
    Publication date: December 20, 2012
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Aadel Chaudhuri, Alex Steven So, David Baltimore, Ryan M. O'Connell
  • Publication number: 20120065245
    Abstract: The present disclosure relates to regulation of functions of hematopoietic stem cells (HSCs) by delivering of miRNAs, including miR-125b, miR-126, and miR-155, to HSCs. For example, in some embodiments, blood output in a mammal can be increased by administering miR-125b, miR-126, and/or miR-155 oligonucleotides. Also disclosed are methods for promoting hematopoietic stem cell engraftment and method for treating a myeloproliferative disorder.
    Type: Application
    Filed: September 12, 2011
    Publication date: March 15, 2012
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David Baltimore, Ryan M. O'Connell
  • Publication number: 20120064122
    Abstract: The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly TH17 and TH1 T cell development, can be modulated by delivery of microRNA-155 (miR-155) or antisense miR-155 to target CD4+ cells or precursor cells. In some embodiments, antisense miR-155 is used to reduce tissue specific autoimmune inflalmmation and to treat autoimmune disease. In addition, miR155 and antisense miR-155 can be used to modulate expression of cytokines from dendritic cells.
    Type: Application
    Filed: September 12, 2011
    Publication date: March 15, 2012
    Inventors: David Baltimore, Ryan M. O'Connell, Daniel Kahn